Skip to main content
$14.70 $0.09 (0.6%)

04:00 PM EDT on 10/22/21

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CAPS Rating: 3 out of 5

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

Current Price $14.70 Mkt Cap $2.6B
Open $14.60 P/E Ratio 0.00
Prev. Close $14.70 Div. (Yield) $0.00 (0.0%)
Daily Range $14.34 - $14.77 Volume 1,631,322
52-Wk Range $3.57 - $18.48 Avg. Daily Vol. 2,278,636

Caps

How do you think NASDAQ:BCRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

256 Outperform
80 Underperform
 

All-Star Players

37 Outperform
24 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BCRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

marsuculix (< 20)
Submitted January 22, 2016

catalyst ahead...

zzlangerhans (99.01)
Submitted April 01, 2013

As I predicted, BioCryst still had a little life left which allowed me to escape my green thumb and flip turn into a red one. 33% jump today, and all because of this:BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary… More

NASDAQ:BCRX VS S&P 500 (SPY)

Fools bullish on NASDAQ:BCRX are also bullish on:

Fools bearish on NASDAQ:BCRX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BCRX.

Recs

0
Member Avatar Paco57 (65.00) Submitted: 7/22/2021 1:17:48 PM : Outperform Start Price: $17.18 NASDAQ:BCRX Score: -19.27

I've been following this one since $4 a share.
Buy this one NOW before it blows up!!!

Recs

0
Member Avatar PensionExtender (39.04) Submitted: 6/30/2020 5:50:50 PM : Outperform Start Price: $4.90 NASDAQ:BCRX Score: +151.42

COVID-19 biotech should continue to grow with oral delivery system of vaccine

Recs

0
Member Avatar mdriver78 (75.38) Submitted: 5/8/2020 1:14:04 PM : Outperform Start Price: $4.36 NASDAQ:BCRX Score: +183.83

Expecting positive sales of over $500 on Berotralstat approval. Plus early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases plus patient dosing underway in galidesivir trial in COVID-19 patients in Brazil. All sounds quite positive and worth a flyer.

Leaderboard

Find the members with the highest scoring picks in BCRX.

Score Leader

cozynite

cozynite (30.88) Score: +824.61

The Score Leader is the player with the highest score across all their picks in BCRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
cozynite 30.88 3/14/2013 Outperform 5Y $1.31 +1,013.74% +189.13% +824.61 0 Comment
MrTwo94 91.36 11/8/2012 Outperform 1Y $1.37 +964.96% +224.33% +740.63 0 Comment
jgrnot 25.56 12/4/2012 Outperform 5Y $1.41 +934.83% +220.61% +714.21 0 Comment
Sytes < 20 5/29/2013 Outperform 3Y $1.60 +811.88% +173.94% +637.93 1 Comment
bearonwallstreet 67.87 5/16/2013 Outperform 5Y $1.70 +758.24% +173.35% +584.89 0 Comment
warrenout3 38.37 12/3/2012 Outperform 5Y $1.63 +795.09% +217.34% +577.76 0 Comment
portefeuille2 99.00 2/16/2016 Outperform 5Y $1.87 +680.21% +138.90% +541.31 0 Comment
Bigsef77 69.68 2/10/2016 2/19/2021 Outperform 5Y $1.89 +671.96% +141.64% +530.31 0 Comment
Roger55125 23.28 4/24/2013 Outperform 5Y $1.80 +710.56% +187.12% +523.44 0 Comment
portefeuille 98.07 2/10/2016 5/31/2021 Outperform NS $1.92 +660.29% +141.62% +518.67 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BCRX.